OncLive - Bringing the Oncology Community Together

At a median follow-up of 14.1 months, the chimeric antigen receptor T-cell therapy tisagenlecleucel achieved an objective response rate of 52% in adult patients with relapsed/refractory diffuse large B-cell lymphoma. Read More >>

2018 EHA: Elotuzumab/Pomalidomide Prolongs PFS in Pretreated Multiple Myeloma

2018 EHA: Upfront Duvelisib Plus FCR Shows Promise in Younger Patients With CLL

2018 EHA: Quizartinib Extends Survival in FLT3-ITD+ Relapsed/Refractory AML

2018 EHA: Polatuzumab Vedotin Plus BR Demonstrates Higher PET-CR in DLBCL

2018 EHA: CD22 CAR T-cell Therapy Effective After CD19 CAR Therapy Failure in Children With B-ALL

View More Stories >>

View Conference Coverage

2018 World Congress on GI Cancer

2018 European Hematology Association Congress

2018 State of the Science Summit on Genitourinary Cancers

2018 ASCO Annual Meeting

2018 ASPHO Conference

Dr. Sallman on APR-246 Plus Azacitidine in TP53-Mutant MDS and AML

Dr. Mato Discusses the Safety and Efficacy of Umbralisib in CLL

$Dr. Cortes on the Results of Quizartinib in Relapsed/Refractory AML$

Dr. Cortes on the Results of Quizartinib in Relapsed/Refractory AML

Dr. Davids Discusses Duvelisib Plus FCR in Young Patients With CLL

Dr. Savin on the Evolution of Biosimilars

Dr. Giri on Genes that Carry a Risk for Prostate Cancer

Dr. McCann on Prognosis for Patients With HER2-Positive Breast Cancer

OncLive houses thousands of videos that provide updates and information.
See more Videos

Managing Advanced Prostate Cancer in the Future

Hereditary Prostate Cancer Testing in Practice

Improvements in Detecting and Treating Metastatic CRPC

Renal Cell Carcinoma: An Evolving Treatment Landscape

OncLive houses thousands of videos that provide updates and information.
See more Videos

HCC: Emerging Therapies

Use of Immunotherapy for HCC

The Evolving Treatment Landscape of CLL

$Relapsed/Refractory CLL: Evaluating Other Novel Agents$

$Treatment of Relapsed/Refractory mHCC$

$Novel Approaches to Treating Relapsed/Refractory CLL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured

The Evolving Landscape of Immunotherapy for NSCLC

A video editorial series that features expert opinions on multiple areas of focus.

View more >>>

Featured

Role of CAR T-Cell Therapy in Relapsed/Refractory ALL

$Role of CAR T-Cell Therapy in Relapsed/Refractory ALL$
A unique opportunity to view lively discussions featuring peer-to-peer exchanges that provide authoritative insights, opinions, and perspectives on important issues facing today's cancer care professionals.

View more >>>

Featured Video

Immunotherapy in the Treatment of Follicular Lymphoma

Ian W. Flinn, MD, PhD; Grzegorz S. Nowakowski, MD; Loretta J. Nastoupil, MD; and Anas Younes, MD, reflect on the value of immunotherapy, immunotherapy combination strategies, and understanding the tumor microenvironment in treating follicular lymphoma.View now

FDA Approvals in Cervical Cancer, Ovarian Cancer, and CLL, and More